Dna Or Rna Fragments Or Modified Forms Thereof (e.g., Genes, Etc.) Patents (Class 536/23.1)
  • Patent number: 10660911
    Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: May 26, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: James J. Collins, Kyle R. Allison, Mark P. Brynildsen
  • Patent number: 10648972
    Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art, including using a solid support, using mass spectrometry, and using quantitative polymerase chain reaction (Q-PCR).
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: May 12, 2020
    Assignee: SomaLogic, Inc.
    Inventors: James R. Heil, Daniel J. Schneider, Daniel T. Nieuwlandt, Sheri K. Wilcox, Dominic Zichi, Todd Gander, Bruce Eaton, Larry Gold
  • Patent number: 10640791
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: May 5, 2020
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10640769
    Abstract: Described are post transcriptionally chemically modified double strand RNAs (MdsRNAs) having more than 30 base pairs. The MdsRNAs inhibit gene expression in target organisms. Also described are methods of making and using MdsRNAs.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: May 5, 2020
    Assignee: nanoSUR LLC
    Inventors: Juan P. Arhancet, Sreevishnu Cheerla, Graciela B. Arhancet, David B. Rozema
  • Patent number: 10633411
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: April 28, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhijian Chen, Lijun Sun, Jiaxi Wu, Heping Shi, Chuo Chen
  • Patent number: 10626419
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: April 21, 2020
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10626439
    Abstract: The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 21, 2020
    Assignee: Translate Bio, Inc.
    Inventors: Michael Heartlein, Frank DeRosa, Anusha Dias
  • Patent number: 10612040
    Abstract: The present disclosure relates to an expression vector for restoring male sterility in a plant. The expression vector comprises a regulatory region sequence operably linked to a heterologous nucleotide sequence.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: April 7, 2020
    Assignees: SHENZHEN INSTITUTE OF MOLECULAR CROP DESIGN, HUNAN WANGHUA AGRICULTERAL BIOTECHNOLOGY CO., LTD., SHENZHEN XINGWANG BIOSEED CO., LTD., XINGWANG INVESTMENT CO., LTD.
    Inventors: Xiaoyan Tang, Zhufeng Chen, Gang Xie, Na Wang, Jiawei Lu, Zaoxia Li
  • Patent number: 10612025
    Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides (AONs) that may be used in the treatment, prevention and/or delay of Usher syndrome type II and/or USH2A-associated non syndromic retina degeneration.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: April 7, 2020
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Hester Catharina Van Diepen, Janne Juha Turunen, Hee Lam Chan
  • Patent number: 10612020
    Abstract: The present disclosure is directed to an artificial mimic miRNA utilizing miRNA. An artificial mimic miRNA is a single-stranded nucleic acid including: a X region; and a Y region, the Y region and the X region being linked, wherein the X region is a guide strand sequence of a mature miRNA or a partial sequence of the guide strand sequence of the mature miRNA and consists of a linking side region (XB) and a non-linking side region (XF) to the Y region, the linking side region (XB) is a sequence that does not cause intramolecular annealing within its region, and the Y region is a sequence that intramolecularly anneals to the non-linking side region (XF) of the X region. According to the artificial mimic miRNA of the present invention, the expression of the target gene can be inhibited.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: April 7, 2020
    Assignee: Tokyo Medical University
    Inventors: Masahiko Kuroda, Shinichiro Ohno
  • Patent number: 10604760
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: March 31, 2020
    Assignee: Mologen AG
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
  • Patent number: 10590178
    Abstract: Chimeric double peptide vaccines are disclosed, useful for inducing active immunity against Candida fungal infections. The chimeric peptide comprises an Fba peptide and an Met6 peptide, covalently linked to one another, with or without an intermediate linker. Fba and Met6 are cell surface components of Candida. When used as a vaccine, the chimeric double peptide vaccine induces stronger protective immunity against fungal infection than does the Fba peptide alone, or the Met6 peptide alone, or a mixture (not covalently linked) of the two peptides.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: March 17, 2020
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventor: Hong Xin
  • Patent number: 10590489
    Abstract: This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: March 17, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: William R. Taylor, Jonathan J. Harrington, Patrick S. Quint, Hongzhi Zou, Harold R. Bergen, III, David I. Smith, David A. Ahlquist
  • Patent number: 10577654
    Abstract: The present invention relates to core-shell particles comprising encapsulated nucleic acids—a sensing sequence and a control sequence; the invention further relates to the use of such particles as a sensing element; to methods for measuring a property of interest in a setting employing such particles; to measuring systems and analytical kits comprising such particles.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: March 3, 2020
    Assignee: ETH Zurich
    Inventors: Robert N. Grass, Wendelin Jan Stark, Gediminas Mikutis, Michela Puddu
  • Patent number: 10577396
    Abstract: An object of the present invention is to conduct a search for a compound to be arranged at a terminal of a peptide nucleic acid effective in detecting a single nucleotide polymorphism. Provided is a tolan compound represented by the following formula (1): wherein R1 represents a phenyl group or a naphthyl group, the phenyl group may have 1 to 5 substituents that are identical to or different from each other, and the naphthyl group may have 1 to 7 substituents that are identical to or different from each other.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: March 3, 2020
    Assignee: Osaka University
    Inventors: Kunihiro Kaihatsu, Nobuo Kato, Kenji Takagi
  • Patent number: 10563197
    Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: February 18, 2020
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ONXEO, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS-SUD 11
    Inventors: Marie Dutreix, Wael Jdey
  • Patent number: 10544419
    Abstract: Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: January 28, 2020
    Assignee: SomaLogic Inc.
    Inventors: Nebojsa Janjic, Daniel W. Drolet, Amy D. Gelinas, Chi Zhang, Michael Vrkljan
  • Patent number: 10538761
    Abstract: Provided herein, inter alia, are double stranded oligonucleotide molecules and methods of making the molecules. The double stranded oligonucleotide molecules include a first oligonucleotide strand comprising a first nucleic acid sequence bound to a second nucleic acid sequence through a first spacer, wherein said second nucleic acid sequence is bound to a third nucleic acid sequence through a second spacer and a second oligonucleotide strand comprising a fourth nucleic acid sequence bound to a fifth nucleic acid sequence through a third spacer, wherein said fifth nucleic acid sequence is bound to a sixth nucleic acid sequence through a fourth spacer, wherein the second nucleic acid sequence and the fifth nucleic acid sequence are hybridized to form a double stranded nucleic acid core of said double stranded oligonucleotide.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: January 21, 2020
    Assignee: City of Hope
    Inventor: Piotr Swiderski
  • Patent number: 10538770
    Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules such as chikungunya viral proteins, such as chikungunya envelope protein E1.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: January 21, 2020
    Assignee: Base Pair Biotechnologies, Inc.
    Inventor: George W. Jackson
  • Patent number: 10538811
    Abstract: An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: January 21, 2020
    Assignee: Central Adelaide Local Health Network Incorporated
    Inventors: Jozef Gecz, Petter Stromme
  • Patent number: 10519514
    Abstract: A method of detecting the presence of Neisseria gonorrhoeae in a sample. The method involves detecting a first target sequence taken from the NGO1642 gene and/or a second target sequence taken from the NGO1012 gene. The method may involve a step of amplifying the target sequence, and may involve hybridising the target sequence to a nucleic acid probe and identifying hybridisation. The method may involve simultaneous detection of other target sequences, e.g. from other pathogens.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: December 31, 2019
    Assignee: Atlas Genetics Limited
    Inventors: Danny Filer, Claire Ferrao, Sharon Chadwick
  • Patent number: 10513734
    Abstract: Devices and methods for detecting, identifying, and sequencing, compounds, complexes, and molecules are described. Electronic detection is combined with optical excitation to determine the presence or identity of an analyte of interest. Embodiments of the invention additionally provide devices and methods that allow highly parallel nucleic acid sequence determination.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: December 24, 2019
    Assignee: Intel Corporation
    Inventors: Xing Su, Mark Oldham
  • Patent number: 10508116
    Abstract: Disclosed herein are Click Nucleic Acid Polymers (CNA-polymers) that comprise repeating dimer, trimer and tetramer units. The disclosed polymers can be used for antisense applications, for example, in treatment of “trinucleotide repeat disorders, i.e., Huntington's Disease and the like.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: December 17, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY
    Inventors: Christopher N. Bowman, Weixian Xi, Sankha Pattanayak
  • Patent number: 10508129
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: December 17, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhijian Chen, Lijun Sun, Jiaxi Wu, Heping Shi, Chuo Chen
  • Patent number: 10493143
    Abstract: The disclosure relates to sexually transmitted disease ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: December 3, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 10487333
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: November 26, 2019
    Assignee: Mologen AG
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
  • Patent number: 10478503
    Abstract: Provided herein are branched oligonucleotides exhibiting efficient and specific tissue distribution, cellular uptake, minimum immune response and off-target effects, without formulation.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: November 19, 2019
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Matthew Hassler, Julia Alterman, Bruno Miguel da Cruz Godinho
  • Patent number: 10478500
    Abstract: The invention relates to RNAi agents, e.g. double-stranded RNAi agents, targeting the HAO1 gene, and method of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1. Described herein are double-stranded RNAi agents which inhibit the expression of a HA01 gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having a HAO1 associated disorder, and uses of such double-stranded RNAi agents. In certain aspects of the invention, substantially all of the nucleotides of an iRNA of the invention are modified.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: November 19, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: William Querbes, Kevin Fitzgerald, Brian Bettencourt, Abigail Liebow, David V. Erbe
  • Patent number: 10465235
    Abstract: The present invention provides a method for detecting interactions between or with any two of at least three target substrates, or any two of at least three features of a target substrate, or a combination of interactions and features of target substrates, by a multiplexed proximity ligation assay, said method comprising: a) for each of the at least three target substrates or features, providing a proximity probe comprising a binding moiety with affinity for the feature or binding site on said substrate, and a proximity probe oligonucleotide coupled on the binding moiety; wherein each of the proximity probe oligonucleotide carries a unique tag sequence; b) mixing the proximity probes with a sample, under a condition to allow binding of each proximity probe to its respective binding site or feature on each of said substrates through the binding moiety, c) simultaneous with, or following step b), forming circularized DNA molecules where any two proximity probes bind sufficiently close to each other on the subst
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: November 5, 2019
    Assignee: NAVINCI DIAGNOSTICS AB
    Inventors: Mats Gullberg, Ola Söderberg, Ulf Landegren, Yanling Liu
  • Patent number: 10457988
    Abstract: The invention relates to novel miRNA markers useful for diagnosis or therapy of disease, in particular for neuronal disorders such as Alzheimer's Disease (AD).
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: October 29, 2019
    Assignee: Siemens Aktiengesellschaft
    Inventors: Andreas Keller, Cord Friedrich Stähler, Christina Backes, Eckart Meese, Petra Leidinger, Andreas Kappel
  • Patent number: 10435430
    Abstract: Described are compounds and methods useful for the treatment and investigation of diseases and disorders associated with expanded repeat-containing RNA molecules. In certain embodiments, compounds and methods useful for the modulation of ATXN-3 pre-mRNA are described. In certain embodiments, compounds and methods useful for the modulation of ATN-1 mRNA are described.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: October 8, 2019
    Assignees: IONIS PHARMACEUTICALS, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Thazha P. Prakash, Jiaxin Hu, Jing Liu, Dongbo Yu, David Corey, Eric E. Swayze
  • Patent number: 10428371
    Abstract: The present invention is intended to provide a novel fluorescent labeled single-stranded nucleic acid, by which the background of an exciton oligomer can be further reduced and the novel use thereof. The present invention relates to a labeled single-stranded nucleic acid having at least two fluorescent atomic group pairs that exhibit an exciton effect. The labeled single-stranded nucleic acid is characterized in that the emission peak wavelength of one of the fluorescent atomic group pairs (fluorescent atomic group pair A) is shorter than the excitation peak wavelength of the other fluorescent atomic group pair (fluorescent atomic group pair B), and the fluorescent atomic group pairs A and B have a Förster resonance energy transfer (FRET) effect. This fluorescent labeled single-stranded nucleic acid is usable as a primer for amplifying a target nucleic acid or a probe to be hybridized with a target nucleic acid.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: October 1, 2019
    Assignee: KABUSHIKI KAISHA DNAFORM
    Inventors: Takeshi Hanami, Yoshihide Hayashizaki, Takahiro Soma, Yasumasa Kimura
  • Patent number: 10421980
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: September 24, 2019
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10415061
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: September 17, 2019
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10392607
    Abstract: The present disclosure provides variant Cas9 proteins, nucleic acids encoding the variant Cas9 proteins, and host cells comprising the nucleic acids. The present disclosure provides systems that include a subject variant Cas9 protein (and/or a nucleic acid encoding the variant Cas9 protein) and a Cas9 guide RNA. In some cases, a subject system includes a PAMmer and/or a donor polynucleotide. The variant Cas9 proteins and the nucleic acids encoding the variant Cas9 proteins are useful in a wide variety of methods, which are also provided. In some embodiments, a variant Cas9 protein includes a RuvC domain, an HNH domain, and a disrupted RuvC/HNH linker region that reduces the RuvC cleavage activity of the protein. In some embodiments, a variant Cas9 protein includes a deletion (of all or a part of the HNH domain) or an insertion (within the HNH domain) that reduces the HNH cleavage activity of the protein.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: August 27, 2019
    Assignee: the regents of the university of california
    Inventors: Samuel H. Sternberg, Jennifer A. Doudna
  • Patent number: 10378017
    Abstract: The invention relates to an oligonucleotide including one or more modified nucleoside bases having the structure -B-L-A wherein for each of the modified nucleosides A is independently a monosaccharide or oligosaccharide, L is a linker molecule, and B is independently a pyrimidine or pyridine base linked to the sugar-phosphate backbone of the oligonucleotide; and wherein the oligonucleotide binds specifically to a carbohydrate-binding monoclonal antibody with an affinity of less than 100 nM. Immunogenic conjugates that include the oligonucleotide, and pharmaceutical compositions that include the oligonucleotide or the immunogenic conjugate are also disclosed. Various method of using the oligonucleotides, immunogenic conjugates, and pharmaceutical compositions are disclosed, including inducing an immune response, inhibiting viral or bacterial infection, treating a cancerous condition, and detecting a neutralizing antibody.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: August 13, 2019
    Assignee: Brandeis University
    Inventor: Isaac J. Krauss
  • Patent number: 10370415
    Abstract: Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (?PNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: August 6, 2019
    Assignee: Carnegie Mellon University
    Inventors: Danith H. Ly, Suresh Kumar Gopalsamy, Arunava Manna
  • Patent number: 10364470
    Abstract: The invention described in the application relates to a long non-coding RNA expressed in cancer. The invention thus provides methods and compositions for evaluating levels of the long non-coding RNA to assess the aggressiveness of a cancer and for modulating levels of the long non-coding RNA.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: July 30, 2019
    Assignee: The Regents of the University of California
    Inventors: Terumi Kohwi-Shigematsu, Yoshinori Kohwi, Ellen C. Ordinario, Michael A. Balamotis, Hye-Jung Han
  • Patent number: 10358658
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: July 23, 2019
    Assignees: The Regents of the University of California, University of Vienna, Emmanuelle Charpentier
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10358459
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2?-arabino-fluoronucleoside and an internucleoside 3?-NH—P(—O)(OR)—O-5? linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2?-arabino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: July 23, 2019
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald G. Schultz
  • Patent number: 10344047
    Abstract: Embodiments are directed to methods for joining oligonucleotides. The methods include joining together one or more oligonucleotides by reacting an alkyne group linked to an oligonucleotide with an azide group linked to an oligonucleotide to form a triazole linkage. The alkyne group is a strained alkyne group. The methods can include ligating together ends of one or more oligonucleotides or cross-linking strands of an oligonucleotide duplex to form the triazole linkage. The methods described allow oligonucleotide strands to be ligated together without the need for a ligase enzyme. The methods can be useful for joining together single strands of DNA, cross-linking complementary strands, cyclizing single and double strands, labeling oligonucleotides with reporter groups, attaching DNA to surfaces, producing analogs of DNA with modified nucleobases and backbones, synthesizing large chemically modified RNA constructs, and creating biochemically active PCR templates.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: July 9, 2019
    Assignee: ATDBIO LTD.
    Inventors: Tom Brown, Afaf Helmy El-Sagheer
  • Patent number: 10336786
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: July 2, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Zhijian Chen, Lijun Sun, Jiaxi Wu, Heping Shi, Chuo Chen
  • Patent number: 10337015
    Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: July 2, 2019
    Assignee: Drexel University
    Inventors: Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens
  • Patent number: 10329318
    Abstract: Described herein are methods of syntheses of phosphorous atom-modified nucleic acids comprising chiral X-phosphonate moieties. The methods described herein provide backbone-modified nucleic acids in high diasteteomeric purity via an asymmetric reaction of an achiral molecule comprising a chemically stable H-phophonate moiety with a nucleoside/nucleotide.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: June 25, 2019
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: Takeshi Wada, Mamoru Shimizu
  • Patent number: 10328146
    Abstract: Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 25, 2019
    Assignee: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
    Inventors: Hildegund C. J. Ertl, Marcio O. Lasaro, Luis C. S. Ferreira
  • Patent number: 10308961
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: June 4, 2019
    Assignees: The Regents of the University of California, University of Vienna, Emmanuelle Charpentier
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10295528
    Abstract: The present invention relates to a method for screening an inhibitor of ATP11C or CDC50A, comprising determining (a) exposure of phosphatidylserine on cell surface, (b) engulfment of cells by macrophages, or (c) cleavage of ATP11C by caspase. The present invention also relates to a method for inducing engulfment of cells by macrophages, comprising inhibiting ATP11C or CDC50A.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: May 21, 2019
    Assignee: KYOTO UNIVERSITY
    Inventors: Shigekazu Nagata, Katsumori Segawa
  • Patent number: 10294520
    Abstract: The present invention features Nicotiana nucleic acid sequences such as sequences encoding constitutive, or ethylene or senescence induced polypeptides, in particular cytochrome p450 enzymes, in Nicotiana plants and methods for using these nucleic acid sequences and plants to alter desirable traits, for example by using breeding protocols.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: May 21, 2019
    Assignee: U.S. Smokeless Tobacco Company LLC
    Inventors: Dongmei Xu, Mark T. Nielsen, Yanxin Shen
  • Patent number: 10294472
    Abstract: The present invention relates to a nucleic acid linker for producing a complex of mRNA, and a protein or a peptide which is encoded by the mRNA, the linker comprising: a spacer portion at the 5?-terminal; a polynucleotide portion hybridizable with at least a part of a sequence of the mRNA; and an arm portion which has a connection portion for the protein or the peptide at the 3?-terminal, in which the spacer portion, the polynucleotide portion, and the arm portion form a single strand, and in which the polynucleotide portion contains a photoreactive base derivative.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: May 21, 2019
    Assignees: THE UNIVERSITY OF TOKYO, NIKON CORPORATION
    Inventors: Takanori Ichiki, Shingo Ueno, Manish Biyani, Ryo Kobayashi, Hirofumi Shiono
  • Patent number: 10273501
    Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: April 30, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Prashant G. Mali, Luhan Yang